Document is current
Any future updates will be listed below
-
Authors
Yuan, Meng-Qi
Song, Le
Wang, Ze-Rui
Zhang, Zi-Ying
Shi, Ming
He, Junli
Mo, Qiong
Zheng, Ning
Yao, Wei-Qi
Zhang, Yu
Dong, Tengyun
Li, Yuanyuan
Zhang, Chao
Song, Jinwen
Huang, Lei
Xu, Zhe
Yuan, Xin
Fu, Jun-Liang
Zhen, Cheng
Cai, Jianming
Dong, Jinghui
Zhang, Jianzeng
Xie, Wei-Fen
Li, Yonggang
Zhang, Bo
Shi, Lei
Wang, Fu-Sheng https://orcid.org/0000-0002-8043-6685
-
Funding
Funding for this research was provided by:
Key Technologies Research and Development Program (2022YFA1105604)
- License Information
-
More Information
Article History
Received: 13 June 2024
Accepted: 14 January 2025
First Online: 25 February 2025
Declarations
:
: (1) Title of the approved project: “Treatment with human umbilical cord-derived mesenchymal stem cells for severe coronavirus disease 2019 (COVID-19).” (2) Name of the institutional approval committee or unit: the Ethics Committee of the Fifth Medical Center, Chinese PLA General Hospital. (3) Approval number: 2020–013-D. (4) Date of approval: February 24, 2020.
: Written informed consent was obtained from all candidates or their legal representatives before the screening process and initiation of any research.
: Not applicable.
: WQY, TYD, and YZ are current employees of Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd. All authors declare no competing interests.
